Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for women's cancers. Co. is focused on developing therapies for the treatment of breast cancer. Co.'s wholly owned, primary product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist and a selective ER degrader. Co. is evaluating OP-1250 in a dose escalation and expansion trial for the treatment of ER-positive, human epidermal growth factor receptor 2-negative breast cancer. The OLMA average annual return since 2020 is shown above.
The Average Annual Return on the OLMA average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether OLMA average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OLMA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|